We sought to assess whether coronary stents have modified the predictive value of demographic, clinical and quantitative coronary angiographic (QCA) predictors of coronary restenosis. BACKGROUND A systematic analysis in a large cohort of registries and randomized trials of the percutaneous transluminal coronary angioplasty (PTCA) and stent era has never been performed.
Coronary restenosis after a percutaneous intervention is a complex multifactorial phenomenon. With the advent of coronary stenting, constrictive vascular remodeling (a major component of the process of restenosis) has been prevented, and restenosis has decreased to a great extent. Nonetheless, restenosis remains an important clinical problem that continues to exert a major negative impact on patients' longterm outcome after percutaneous coronary interventions. Several demographic, clinical, quantitative coronary angiographic (QCA) and intravascular ultrasound (IVUS) variables have been described previously as predictors of restenosis in either percutaneous transluminal coronary angioplasty (PTCA) or stent populations (1) (2) (3) (4) (5) (6) (7) (8) .
From the mechanistic point of view, there is a clear difference between restenosis after PTCA alone and PTCA plus stenting. As assessed by IVUS studies, the prevailing mechanism in restenosis after PTCA alone is arterial remodeling, with late vessel contraction responsible for Ͼ60% of late lumen loss (9) , whereas accelerated intimal hyperplasia predominantly causes in-stent restenosis (10) .
Previous reports, which are hampered by their small sample sizes, have analyzed a limited number of potential predictors of restenosis in either the stent or PTCA population analyzed separately. The aim of this study was to assess to what extent the introduction of coronary stents has modified the predictive value of previously identified demographic, clinical and QCA predictors of coronary restenosis in the balloon era. We combined two patient populations: patients treated with PTCA only (PTCA population) and patients who also had coronary stents implanted (stent population).
METHODS
Patients were selected from 19 different studies: six randomized trials comparing the use of active medications aimed at coronary restenosis prevention after PTCA alone or PTCA plus stenting with placebo (Coronary Artery Restenosis Prevention On Repeated Thromboxane A 2 -antagonism [CARPORT] study [11] [29] ). These 19 studies were chosen because they are highly representative of the randomized trials and registries of PTCA and coronary stenting that have been performed in the past decade, antedating the use of intracoronary brachytherapy. In eight studies, treatment of more than one lesion per patient was allowed (CARPORT, MERCATOR, PARK, MARCATOR, BENESTENT-2, FLARE, stent PAMI, MAGIC 5-L); the remaining studies included only patients with a single lesion. For patients with multilesion PTCA or multilesion coronary stenting, all lesions were analyzed, and each was considered independently.
Patients were included in this analysis if they had three adequate angiograms-one immediately before the intervention, one immediately after and one at six-month followup. Patients with an unsuccessful procedure or with a lesion in a saphenous vein graft were excluded.
Off-line analysis of angiographic outcomes was done using identical and standardized methods of data acquisition and analysis and definitions of the variables in the same core laboratory (Cardialysis, Rotterdam, The Netherlands) using the Cardiovascular Angiography Analysis System II (CAAS II) (Pie Medical, Maastricht, The Netherlands) (30) . Definitions. Procedural success was defined as a postprocedural diameter stenosis (post-DS) Ͻ50% on visual inspection in the early trials (CARPORT, MERCATOR, PARK, MARCATOR and FLARE). Subsequently (BENESTENT-1, BENESTENT-2 pilot, EASI, BENESTENT-2, stent PAMI pilot, WEST-1, WEST-2, Wallstent native, stent PAMI, ROSE, DUET, TRAPIST and SOPHOS), procedural success was defined as Ͻ50% post-DS by on-line QCA and no occurrence of an inhospital major adverse cardiac event (death, acute myocardial infarction, coronary artery bypass graft surgery [CABG] or repeat PTCA), and finally, in the latest trial (MAGIC 5-L), procedural success was reset to Ͻ20% post-DS by on-line QCA in the absence of an in-hospital major adverse cardiac event. Coronary restenosis was defined uniformly in all but one randomized trial according to the binary criteria with a cut-off point Ն50% DS at follow-up (31) . In this randomized trial (CARPORT), a noncategorical approach was used, and restenosis was defined as a loss of Ն0.72 mm in the MLD from post-PTCA to six-month follow-up. For standardization purposes, we computed the binary restenosis rate of this trial based on the DS on the follow-up angiogram. The standard definitions for proximal and distal segments of the right coronary artery, left anterior descending coronary artery (LAD) and left circumflex coronary coronary artery have been described elsewhere (32) . The pre-procedural reference diameter (pre-RD) was obtained by the interpolation method, and the lesion length was defined by curvature analysis (33) . Statistical analysis. Statistical analysis was performed using the SAS version 8.0 software package (SAS Institute, Cary, North Carolina). To test for differences in baseline variables across the studies, the Kruskal-Wallis test (continuous data) and the chi-square test (categorical data) were applied. Univariate and multivariate logistic regression analyses were used to evaluate the relationships between demographic data, clinical characteristics, stent use, QCA variables and the six-month outcome of angiographic occurrence of restenosis, which was coded as a binary variable according to the partial method. The stent length was Յ15 mm (with a minimal length of 8 mm) in 68% of patients with stents. In the remaining patients, the stent length varied from 18 mm (DUET study) to 48 mm (MAGIC 5-L study). For restenosis assessment, these two different subsets of the stent population (Յ15 and Ͼ15 mm) were compared with the PTCA population.
Abbreviations and Acronyms
CABG ϭ coronary artery bypass graft surgery CI ϭ confidence interval DS ϭ diameter stenosis IVUS ϭ intravascular ultrasound LAD ϭ left anterior descending coronary artery MLD ϭ minimal lumen diameter PTCA ϭ percutaneous transluminal coronary angioplasty OR ϭ odds ratio QCA ϭ quantitative coronary angiography RD ϭ reference diameter
Interaction terms between demographic data, clinical characteristics, QCA variables and stent use were introduced to evaluate the influence of coronary stents on the predictors of coronary restenosis. To prevent associations by chance, p Ͻ 0.001 was considered significant for these interaction terms. All variables were entered into the multivariate model, irrespective of the results of the univariate analysis (excluding the interaction terms in which the specified level of significance was not reached). The final multivariate model was constructed by backward deletion of the least significant variables, while the Akaike criterion was applied-that is, the applied threshold of significance depended on the degrees of freedom (df) associated with the variable at hand; if df ϭ 1, then p ϭ 0.157 (34) . The predictive accuracy of the final multivariate model was evaluated using the C-index (35) and the goodness of fit of the model was tested with the Hosmer-Lemeshow goodness-of-fit test (36) .
RESULTS
A total of 9,120 treated lesions in 8,156 patients were considered for this study. Sixty-four percent of the patients were treated with PTCA only (PTCA population: n ϭ 5,230; 6,110 lesions), and coronary stents were implanted in 36% of patients (stent population: n ϭ 2,926; 3,010 lesions).
The restenosis rate at six-month QCA follow-up was 35% after PTCA, compared with 19% after stenting. The baseline characteristics of the PTCA and stent populations are described in Table 1 .
As might be expected (in such a heterogeneous population), the demographic data and clinical characteristics were significantly different across registries and trials. The patients' median age increased from 57 years in the oldest trial (CARPORT) to 62 years in the latest trial (MAGIC 5-L). The percentage of diabetic patients varied from 5.8% (MERCATOR) to 17% (Wallstent native); no temporal trend was observed for this condition. The prevalence of previous CABG varied from 1% (BENESTENT-1 and stent PAMI pilot) to 5.6% (MARCATOR).
The pre-and post-procedural and six-month follow-up QCA variables are described in Table 2 . It is important to note that the restenosis rate decreased from 38% in PARK (1993, PTCA) to 12.8% in WEST-2 (1998, PTCA plus stenting). This decrease in the restenosis rate was observed despite a parallel increase in the length of treated lesions, from a median of 5.8 mm in MERCATOR (1992, PTCA) up to 14.3 mm in MAGIC 5-L (1999, PTCA plus AMI ϭ acute myocardial infarction; CSA ϭ chronic stable angina; LAD ϭ left anterior descending coronary artery; LCx ϭ left circumflex coronary artery; MI ϭ myocardial infarction; MVD ϭ multiple-vessel disease; PTCA ϭ percutaneous transluminal coronary angioplasty; PVD ϭ peripheral vascular disease; RCA ϭ right coronary artery; UA ϭ unstable angina. Favorable predictors common to the PTCA and stent populations were previous CABG, stent use, stent length Ͻ15 mm, stent length Ն15 mm and a large pre-procedural MLD (pre-MLD); unfavorable predictors were weight, body mass index, diabetes mellitus, multi-vessel disease, lesion length and a high residual post-DS. Predictors specific for the PTCA population were a large post-MLD as favorable and a severe pre-DS as unfavorable. Favorable predictors specific for the stent population were a large post-MLD and a large pre-RD.
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In the multivariate analysis, the model with the best predictive accuracy and that best fit the entire population (Table 3) The C-index for predictive accuracy initially demonstrated a poor ability for demographic and clinical characteristics to discriminate between patients who did and those who did not develop coronary restenosis (C-index ϭ 0.51), which subsequently improved slightly when the postprocedural variables (mainly QCA) were added to the final multivariate model (C-index ϭ 0.63).
DISCUSSION
In this study, several clinical and QCA predictors of coronary restenosis were identified in a large number of patients in two distinct populations. Significant demographic and clinical predictors of restenosis did not differ between patients treated with PTCA alone and those with stents. In contrast, three QCA variables were differentially associated with restenosis. A large post-MLD was a favorable predictor in both the PTCA and stent populations, but the protective effect was more marked in the stent population. A severe pre-DS was an unfavorable predictor in the PTCA population only, and a large pre-RD was a favorable predictor in the stent population. Clinical predictors. DIABETES MELLITUS. Patients with diabetes mellitus have been repeatedly shown to have an increased risk of developing restenosis, as compared with nondiabetics (37, 38) . The mechanisms responsible for the increased proclivity for restenosis in the diabetic patient are not completely understood. In an IVUS analysis, it was concluded that the main reason for increased restenosis in diabetic patients was exaggerated intimal hyperplasia in both stented and nonstented lesions (38) . However, data from Van Belle et al. (39) do not support this hypothesis, but rather favor vessel remodeling (i.e., vessel constriction) as the main mechanism.
Alterations in the expression of components of the fibrinolytic system within the lesions of diabetic patients may also be an important determinant of restenosis. Sobel et al. (40) demonstrated, in a detailed immunohistochemical analysis of coronary atherectomy samples, a disproportionate elevation of concentrations of the prothrombotic plasminogen activator inhibitor type 1, which may induce Data are presented as the median value (25th, 75th percentiwles) or as the mean value Ϯ SD. Pre-and post-DS ϭ pre-and post-procedural diameter stenosis; pre-and post-MLD ϭ pre-and post-procedural minimal lumen diameter; pre-RD ϭ pre-procedural reference diameter; PTCA ϭ percutaneous transluminal coronary angioplasty. restenosis by clot-associated mitogens. More recently, atherectomy specimens from restenotic lesions after PTCA showed a reduced intimal hypercellular tissue content in patients with diabetes (41). Collagen-rich sclerotic content is increased, suggesting an accelerated fibrotic rather than a proliferative response in diabetics with restenosis after PTCA, putting into context again the fundamental importance of vessel remodeling in diabetics.
PREVIOUS CABG. In the present study, restenosis was less likely to occur in the subgroup of patients with previous CABG. Vein graft intervention was excluded from our analysis. We can only speculate about possible mechanisms leading to less restenosis in patients with previous CABG. Some baseline characteristics differed between patients with and those without previous CABG, such as a lower percentage of current smokers (14% vs. 26%) and a higher proportion of patients with chronic stable angina (85% vs. 75%). However, these variables did not independently predict restenosis by univariate analysis. The association is weak, and residual confounding factors may have played a role. The interaction term between stent use and each of the variables was significant (p Ͻ 0.001) if the PTCA (solid triangles) and stent (solid squares) populations each had two ORs (with 95% CIs) presented. AMI ϭ acute myocardial infarction; BMI ϭ body mass index; CABG ϭ coronary artery bypass graft surgery; CSA ϭ chronic stable angina; DM ϭ diabetes mellitus; DS ϭ diameter stenosis; HTA ϭ hypertension; LAD ϭ left anterior descending coronary artery; LCx ϭ left circumflex coronary artery; MI ϭ myocardial infarction; MLD ϭ minimal lumen diameter; MVD ϭ multi-vessel disease; PVD ϭ peripheral vascular disease; RCA ϭ right coronary artery; RD ϭ reference diameter; UA ϭ unstable angina. LOCATION OF TREATED LESION. The impact of the location of the treated lesion on restenosis has been described in previous PTCA (1) and stent (2) studies. Evidence is conflicting, but most often, it is claimed that LAD lesions are more prone to restenosis. In one study (1) , an OR of 1.7 (95% CI 1.5 to 2.1) was found for proximal, as compared with nonproximal LAD lesions treated with PTCA alone in a sample of 2,500 patients. Another analysis of binary restenosis at follow-up in 1,399 lesions reported an OR of 1.31 for stented lesions in the LAD (2). In these two previous studies, a positive association was found, whereas others noted that the location of the stented lesion had no impact on restenosis after coronary stenting (3) . After a detailed analysis, our results indicate that there is no evidence to support the idea that a given treatment location plays a role in the restenotic process. (50) and drug-eluting stents (51), have become available recently. Patients treated with these modalities represent a distinctive population in which the results of our analyses should not be applied.
Conclusions. There are no major differences in demographic and clinical predictors of coronary restenosis between PTCA and stent populations. In the modern (stent) era, a severe pre-DS is no longer an unfavorable predictor of restenosis. Still important, but more so in the stent population, is a large post-MLD (optimal result). Finally, a larger pre-RD became a favorable predictor with the advent of stenting.
